Research Analysts Offer Predictions for VKTX Q1 Earnings

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for Viking Therapeutics in a note issued to investors on Thursday, February 6th. HC Wainwright analyst J. Pantginis forecasts that the biotechnology company will post earnings per share of ($0.26) for the quarter. HC Wainwright has a “Buy” rating and a $102.00 price target on the stock. The consensus estimate for Viking Therapeutics’ current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for Viking Therapeutics’ Q2 2025 earnings at ($0.35) EPS, Q3 2025 earnings at ($0.40) EPS, Q4 2025 earnings at ($0.43) EPS and FY2025 earnings at ($1.51) EPS.

Several other analysts have also issued reports on the stock. Raymond James lifted their target price on shares of Viking Therapeutics from $122.00 to $125.00 and gave the company a “strong-buy” rating in a research report on Thursday, February 6th. Citigroup assumed coverage on shares of Viking Therapeutics in a research report on Friday. They issued a “neutral” rating and a $38.00 target price on the stock. Piper Sandler dropped their target price on shares of Viking Therapeutics from $74.00 to $71.00 and set an “overweight” rating on the stock in a research report on Thursday, February 6th. B. Riley reiterated a “buy” rating and issued a $96.00 target price (down previously from $109.00) on shares of Viking Therapeutics in a research report on Friday. Finally, Maxim Group dropped their target price on shares of Viking Therapeutics from $120.00 to $70.00 and set a “buy” rating on the stock in a research report on Friday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Viking Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $96.92.

Viking Therapeutics Stock Down 7.3 %

Shares of NASDAQ VKTX opened at $30.17 on Monday. The company’s 50-day simple moving average is $39.63 and its 200-day simple moving average is $53.68. Viking Therapeutics has a 52-week low of $29.82 and a 52-week high of $99.41. The firm has a market cap of $3.36 billion, a price-to-earnings ratio of -30.17 and a beta of 0.90.

Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings results on Wednesday, February 5th. The biotechnology company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.05). During the same quarter in the prior year, the business posted ($0.25) EPS.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in VKTX. Truist Financial Corp grew its holdings in Viking Therapeutics by 357.1% during the 2nd quarter. Truist Financial Corp now owns 26,049 shares of the biotechnology company’s stock worth $1,381,000 after acquiring an additional 20,350 shares in the last quarter. Sanctuary Advisors LLC purchased a new position in Viking Therapeutics during the 2nd quarter worth $190,000. GAMMA Investing LLC raised its position in Viking Therapeutics by 124.6% during the 3rd quarter. GAMMA Investing LLC now owns 438 shares of the biotechnology company’s stock worth $28,000 after buying an additional 243 shares during the last quarter. CWM LLC increased its holdings in shares of Viking Therapeutics by 34.1% in the 3rd quarter. CWM LLC now owns 2,036 shares of the biotechnology company’s stock valued at $129,000 after purchasing an additional 518 shares in the last quarter. Finally, Exchange Traded Concepts LLC increased its holdings in shares of Viking Therapeutics by 320.3% in the 3rd quarter. Exchange Traded Concepts LLC now owns 69,503 shares of the biotechnology company’s stock valued at $4,400,000 after purchasing an additional 52,968 shares in the last quarter. Institutional investors and hedge funds own 76.03% of the company’s stock.

Insiders Place Their Bets

In other Viking Therapeutics news, COO Marianna Mancini sold 54,215 shares of Viking Therapeutics stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $42.75, for a total transaction of $2,317,691.25. Following the transaction, the chief operating officer now directly owns 374,134 shares of the company’s stock, valued at $15,994,228.50. The trade was a 12.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Greg Zante sold 50,309 shares of Viking Therapeutics stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $42.75, for a total transaction of $2,150,709.75. Following the transaction, the chief financial officer now directly owns 165,259 shares in the company, valued at $7,064,822.25. This trade represents a 23.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 299,014 shares of company stock valued at $12,782,849 over the last ninety days. Company insiders own 4.70% of the company’s stock.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.